Analysis
Chinese AI lab DeepSeek is in talks for a new private funding round targeting a pre-money valuation of at least 480 billion yuan, or roughly $71 billion, according to Bloomberg -- a sharp jump from the roughly $50 billion valuation in its previous round, and coming only weeks after the company closed a record $7 billion first external financing. DeepSeek is reportedly seeking to raise at least 10 billion yuan, though the final amount could grow depending on investor demand.
Simultaneously, and unusually, DeepSeek is preparing to file for an IPO in mainland China as soon as this year, a move that could set up a market debut as early as 2027. The company has begun discussions with accounting and banking advisers as it advances listing preparations. Running a growth-stage private round and active IPO prep at the same time is an aggressive sequencing choice: it suggests DeepSeek wants to lock in additional private capital, and the valuation discipline that comes with a fresh primary round, before public markets get a chance to price the company on their own terms.
“Simultaneously, and unusually, DeepSeek is preparing to file for an IPO in mainland China as soon as this year, a move that could set up a market debut as early as 2027.”
The move lands alongside Moonshot AI's own parallel IPO preparations, and Fortune has already framed 2026 as a breakout year for Chinese AI labs racing toward public listings -- a trend playing out even as the White House publicly accuses Moonshot of covertly distilling Anthropic's Fable model, an unproven claim Moonshot disputes. That regulatory tension adds real uncertainty to how any Chinese AI lab's public listing, DeepSeek's included, will be received by Washington and by international investors weighing exposure to companies operating under both potential export-control scrutiny and direct US policy accusations against sector peers.
DeepSeek's valuation trajectory -- from roughly $50 billion to a targeted $71 billion in a matter of months -- also puts it in the same rarefied tier of AI-lab re-pricing that Anthropic and OpenAI have seen domestically, suggesting investor appetite for frontier AI exposure isn't confined to US labs even as geopolitical tension around Chinese AI technology intensifies.
What to watch: whether the new funding round closes at the reported $71 billion target given how fluid AI valuations have proven all year, whether DeepSeek's IPO filing timeline holds given the current US-China AI policy tension, and whether Bloomberg's caveat -- that both the fundraising and IPO timing could still change -- proves prescient.
